AstraZeneca PLC (ETR:ZEG)
Germany · Delayed Price · Currency is EUR | Market Cap | 243.56B +20.0% |
| Revenue (ttm) | 49.54B +13.5% |
| Net Income | 8.01B +44.7% |
| EPS | 5.13 +45.0% |
| Shares Out | n/a |
| PE Ratio | 30.40 |
| Forward PE | 18.58 |
| Dividend | 2.91 (1.83%) |
| Ex-Dividend Date | Aug 7, 2025 |
| Volume | 3,764 |
| Average Volume | 10,656 |
| Open | 157.10 |
| Previous Close | 157.10 |
| Day's Range | 157.10 - 160.15 |
| 52-Week Range | 111.00 - 166.30 |
| Beta | 0.19 |
| RSI | 48.38 |
| Earnings Date | Feb 10, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial numbers in USD Financial StatementsNews
AstraZeneca is listing in New York, as Big Pharma balances the huge U.S. market with China's tempting innovation
AstraZeneca announces multibillion dollar investments in China as Big Pharma is increasingly looking east for innovation.
Precidian Funds, Announces the Liquidation of AstraZeneca PLC ADRhedged
NEW YORK CITY, NEW YORK / ACCESS Newswire / January 30, 2026 / Precidian Funds today announced that AstraZeneca PLC ADRhedged (the "Series") will liquidate following AstraZeneca PLC's announcement ...
AstraZeneca Agrees Up to $18.5 Billion Obesity Drug Deal in China
AstraZeneca Agrees Up to $18.5 Billion Obesity Drug Deal in China
AstraZeneca Expands Weight Loss Push With Eight-Program China Collaboration
On Friday, AstraZeneca Plc (NASDAQ: AZN) announced that it has strengthened its weight management portfolio through a new strategic collaboration agreement with CSPC Pharmaceuticals Group Limited to ...
AstraZeneca (AZN) Expands Weight Management Initiatives with CSPC Partnership
AstraZeneca (AZN) Expands Weight Management Initiatives with CSPC Partnership
FTSE 100 Holds Steady as Tech and metals Wobble
FTSE 100 steady despite tech and metals pressure, AstraZeneca deal, LSEG MoU, geopolitical tensions dominate The post FTSE 100 Holds Steady as Tech and metals Wobble appeared first on Investomania .
AstraZeneca (AZN) Secures $18.5B Deal for Obesity Drug Development
AstraZeneca (AZN) Secures $18.5B Deal for Obesity Drug Development
AstraZeneca strikes up to $18.5B obesity drug deal with China’s CSPC Pharmaceutical
AstraZeneca’s $18.5B obesity-drug deal with CSPC secures ex-China rights to once-monthly GLP-1/GIP assets.
AstraZeneca secures tie-up with Chinese firm for weight loss drugs
The deal includes giving AstraZeneca access to the exclusive global rights, outside China, to CSPC’s once-a-month weight management jabs.
AstraZeneca Strikes Deal With CSPC To Boost Obesity And Diabetes Therapies
LONDON (dpa-AFX) - AstraZeneca PLC (AZN) said on Friday it has entered a strategic collaboration with CSPC Pharmaceuticals, paying $1.2 billion upfront to expand its weight-management pipeline. Th...
AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China's CSPC
The agreement to gain rights outside of China to a portfolio of experimental obesity and diabetes drugs could be valued at billions of dollars.
World leaders descend on Beijing as 2026 kicks off, hedging against U.S. disruptions
At least five world leaders have visited Beijing in January alone. The high-level visits come as countries navigate tense U.S. relations.
AstraZeneca (AZN) Partners with CSPC for Obesity Drug Development
AstraZeneca (AZN) Partners with CSPC for Obesity Drug Development
China's CSPC Pharmaceutical, AstraZeneca partner on long-acting obesity drugs
China's CSPC Pharmaceutical inks deal with AstraZeneca for weight loss therapy
CSPC Pharmaceutical Group said on Friday it had entered an agreement with UK drugmaker AstraZeneca for the development of innovative long-acting peptide medicines for obesity and weight-related condit...
Oakmark Global Strategy Outperforms, Adds AstraZeneca (AZN) and Gartner (IT)
Oakmark Global Strategy Outperforms, Adds AstraZeneca (AZN) and Gartner (IT)
AstraZeneca to invest £11bn in China after rowing back on UK expansion
Move comes after Britain’s biggest drugmaker’s dispute with government over drug pricing Britain’s biggest drugmaker AstraZeneca is to invest $15bn (£11bn) in China, it announced during Keir Starmer’s...
Oakmark Global Strategy adds AstraZeneca, exits General Motors in Q4
AstraZeneca Bets Big On China With Massive $15 Billion Investment
AstraZeneca Plc (NASDAQ: AZN) on Thursday announced $15 billion investment in China through 2030 to expand medicines manufacturing and R&D. In July 2025, AstraZeneca announced it would invest $50 bil...
AstraZeneca To Invest $15 Bln In China To Advance Medicines Manufacturing And R&D
LONDON (dpa-AFX) - AstraZeneca PLC (AZN), Thursday announced announced $15 billion investment in China through 2030 to expand medicines manufacturing and R&D, leveraging the country's scientific e...
AstraZeneca unveils US$15 billion China investment plan as Starmer visits Beijing
British-Swedish pharmaceutical giant AstraZeneca said on Thursday it plans to invest US$15 billion in China through 2030, signalling renewed momentum in UK-China commercial ties. The investment – the ...
AstraZeneca to invest £11bn in China after snubbing Britain
Pharmaceutical giant announces plans during Sir Keir Starmer’s visit to Beijing
AstraZeneca (AZN) Unveils $15B Expansion Plan in China
AstraZeneca (AZN) Unveils $15B Expansion Plan in China
AstraZeneca (AZN) Unveils $15 Billion Investment Plan in China
AstraZeneca (AZN) Unveils $15 Billion Investment Plan in China